story of the week
Sacituzumab Govitecan in HR+/HER2− Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
J. Clin. Oncol 2022 Aug 26;[EPub Ahead of Print], HS Rugo, A Bardia, F Marmé, J Cortes, P Schmid, D Loirat, O Trédan, E Ciruelos, F Dalenc, PG Pardo, KL Jhaveri, R Delaney, O Fu, L Lin, W Verret, SM TolaneyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.